// STATE LEGISLATION TRACKER

California AB 782: Pharmacies: compounding.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Vetoed

State: California
Bill: AB 782
Filed: 2023-02-13
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

AB 782 would have narrowed California's definition of pharmacy compounding for simple pharmacy actions like manufacturer-directed reconstitution, tablet splitting or crushing, capsule opening, and medication flavoring. It was vetoed, so it does not change access to compounded peptides, off-label prescribing, telehealth prescribing, clinician scope, 503A/503B rules, controlled substances, or prescription monitoring.

Key Points

No current change for compounded peptide access in California
The bill focused on flavoring and simple dosage handling, not peptides
It would not expand telehealth prescribing or off-label prescribing
It would not change NP, naturopathic, or physician scope
It was vetoed, so California compounding standards remain in place

What to Watch For

Note Future California pharmacy bills may revisit what counts as compounding under USP standards.

Concern California remains strict on compounding standards, which can affect pharmacies serving peptide users.

Note This bill does not appear to affect controlled substances or prescription monitoring.

Where the Bill Stands

The bill passed the Legislature but was vetoed by Governor Newsom on October 8, 2023, so it did not become law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws